Sterogene Bioseparations

Executive Summary

Sterogene Bioseparations is a U.S.-based private company specializing in chromatography resins for biologics purification, including its patented Direct Capture™ technology. Founded in 1990 and headquartered in San Marcos, California, the company offers concierge-style solutions for antibody purification, plasma protein purification, contamination removal, and extracorporeal devices. Despite being established for over three decades, Sterogene remains privately held with limited public financial or pipeline disclosures. Its products serve the growing biologics market, which demands cost-effective purification solutions as the industry shifts toward continuous manufacturing and gene therapies. The company's niche focus on custom resin development positions it as a potential partner for biopharma firms seeking specialized purification technologies. However, the lack of recent funding rounds or major partnership announcements suggests either a steady organic growth trajectory or a quiet approach to market expansion. Given the competitive landscape dominated by larger players like Cytiva and Thermo Fisher, Sterogene's differentiation lies in its flexible, small-to-mid-scale resin production and technical support.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a Top-20 Biopharma for Direct Capture™ Integration60% success
• Q1 2027FDA Approval for a New Resin Designed for Continuous Bioprocessing50% success
• Q4 2026Launch of a Resin Product Line Optimized for Gene Therapy Vector Purification40% success